LV Dong-jie,WANG Lan,HAN Chun,et al.Toxicity analysis for esophagus in locally advanced non-small cell lung cancer(NSCLC) treatment using three dimensional conformal radiotherapy combined with concurrent chemotherapy[J].Chinese Journal of Radiological Medicine and Protection,2010,30(2):185-188
Toxicity analysis for esophagus in locally advanced non-small cell lung cancer(NSCLC) treatment using three dimensional conformal radiotherapy combined with concurrent chemotherapy
Received:May 18, 2009  
DOI:
KeyWords:Lung neoplasm  Conformal radiotherapy  Chemotherapy  Acute radiation esophagitis
FundProject:河北省普通高校强势特色学科课题(冀教高[2005]52号)
Author NameAffiliationE-mail
LV Dong-jie Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhung 050011, China  
WANG Lan Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhung 050011, China  
HAN Chun Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhung 050011, China hanchun2006@126.com 
GAO Chao Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhung 050011, China  
LI Xiao-ning Department of Radiation Oncology, Fourth Hospital of Hebei Medical University, Shijiazhung 050011, China  
Hits: 4340
Download times: 2255
Abstract::
      Objective To investigate the radiation toxicity for esophagus in stage III NSCLC treatment using three dimensional conformal radiotherapy(3D CRT) combined with concurrent chemotherapy, and to obtain the relevant factors that can be regareded as predictors to complications of esophagus. Methods From Sep 2006 to Dec 2008, 52 patients with stage III NSCLC received 3D CRT plus concurrent chemotherapy of navelbine+cisplatin(NP) with prescription of 60 Gy/30 fractions, and chemotherapy at 1 and 5 week. Univariate and multivariate analysis and ROC(receiver operating characteristic curves) were performed to assess theassociation ofradiation-induced esophagitis and the correlated factors. Results Of all the patients, 84.6%(44/52) developed radiation esophagitis including grade 1 for 16 patients, grade 2 for 12 patients and grade 3 for 16 patients, without grade 4 developed. The correlative factors comprised of mean esophagus dose(MED), the LETT40, LETT45, LETT50, LETT55, LETT60, V40, V45, V50, V55 and V60 of esophagus according to Spearman correlative analysis, and all the 11 factors could predict radiation esophagitis according to univariate analysis(χ2=7.355-8.690, P<0.05). Only V55 was found independently associated with esophagitis according to multivariate analysis. ROC analysis indicated that the cut-off point of the curve was 26% with the area under ROC curve of 0.725(P=0.006). For the patients with esophageal V55>26%, 21 of 31(67.7%) developed 2 or 3 grade radiation esophagitis, while for the patients with V55≤26%, only 7 of 21(33.3%) developed severe esophagitis. Conclusions 3D CRT combined with concurrent chemotherapy for patients with stage III NSCLC may develop severe radiation esophagitis. Dosimetric parameters (MED, LETT40, LETT45, LETT50, LETT55, LETT60, V40, V45, V50, V55 and V60 ) were important to predict the radiation-induced esophagitis. According to multivariate analysis, V55 may be the most valuable predictor. When the value of V55 excluded 26%, the probability of esophagitis of grade 2 and 3 may increase notably.
HTML  View Full Text  View/Add Comment  Download reader
Close

Copyright©    Editorial Office of Chinese Journal of Radiological Medicine and Protection    

Beijing ICP No. 05020547 -2

Address: 2 Xinkang Street, Dewai, Beijing 100088, China

Telephone:010-62389620; Email:cjrmp@cjrmp.sina.net

Technical Support:Beijing E-tiller CO.,LTD.

Visitors:11565577  On-line:0

v
Scan QR Code
&et=BB94E932C3A0C1D96BCDFCDE9ADC9ACF878C9DA7D59940E1AD7FC2FE854274EC69BE40CF6BDFF1F53E6575A9910F0D8D8071F368C979F55348E0EDE3F6C33A458E1EB19642F174AA01A69500582995E08403D69361D9A591590C93E02C012C60C48EB9DEF406DE994DA3FD306B4613D9E7CBB05CC3BA9C71660FB83F16A6FA61EFC820D9C6724954A5B7D66EC133FAFC05F39C9A265B815AA1D25685616B464205FD0257DA024AC2F21F0724B573AF9B50C440DD9C59B067&pcid=A9DB1C13C87CE289EA38239A9433C9DC&cid=D4D466D60FDC1A5A&jid=5E4353813E091AB841B02B880782B82C&yid=140ECF96957D60B2&aid=A0C782AB0DD197A40EC92D7309DA4E2C&vid=&iid=0B39A22176CE99FB&sid=D46BA3D3D4B3C585&eid=847B14427F4BF76A&fileno=20100220&flag=1&is_more=0"> var my_pcid="A9DB1C13C87CE289EA38239A9433C9DC"; var my_cid="D4D466D60FDC1A5A"; var my_jid="5E4353813E091AB841B02B880782B82C"; var my_yid="140ECF96957D60B2"; var my_aid="A0C782AB0DD197A40EC92D7309DA4E2C";